BioGend Therapeutics Co., Ltd. (TPEX:6733)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
29.00
0.00 (0.00%)
Apr 28, 2026, 1:30 PM CST
10.48%
Market Cap 3.61B
Revenue (ttm) 222.34M
Net Income (ttm) -84.61M
Shares Out 124.36M
EPS (ttm) -0.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 202,367
Average Volume 218,138
Open 29.00
Previous Close 29.00
Day's Range 28.90 - 29.60
52-Week Range 26.25 - 49.15
Beta 0.28
RSI 24.13
Earnings Date May 8, 2026

About BioGend Therapeutics

BioGend Therapeutics Co., Ltd. engages in the research and development, and sale of orthopedic medical devices and related products. The company offers RevoCart, an autologous cartilage repair system; and SoufCut, an autologous adipose tissue collection system. It develops BiG-001, an osteoinductive bone graft substitute; BiG-006 for lumbar interbody fusion; and BiG-009, an autologous cartilage repair system for articaular cartilage. The company operates in Taiwan, Hongkong, Chinese Mainland, and Malaysia. BioGend Therapeutics Co., Ltd. was fou... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 27
Stock Exchange Taipei Exchange
Ticker Symbol 6733
Full Company Profile

Financial Performance

In 2025, BioGend Therapeutics's revenue was 222.34 million, an increase of 32.62% compared to the previous year's 167.65 million. Losses were -84.61 million, -27.36% less than in 2024.

Financial Statements

News

There is no news available yet.